Literature DB >> 35831899

Combined associations of family history and self-management with age at diagnosis and cardiometabolic risk in 86,931 patients with type 2 diabetes: Joint Asia Diabetes Evaluation (JADE) Register from 11 countries.

Johnny T K Cheung1, Eric Lau2,3, Cyrus C T Tsui1, Edmond L N Siu1, Naomi K W Tse1, Nicole Y L Hui1, Ronald C W Ma2,4,5, Alice P S Kong2,4,5, Amy Fu3, Vanessa Lau3, Weiping Jia6, Wayne H H Sheu7, Leorino Sobrepena8, K H Yoon9, Alexander T B Tan10, Yook-Chin Chia11,12, Aravind Sosale13, Banshi D Saboo14, Jothydev Kesavadev15, Su-Yen Goh16, Thy Khue Nguyen17, Yotsapon Thewjitcharoen18, Raymond Suwita19, Andrea O Y Luk2,3,4, Aimin Yang3,4, Elaine Chow3,4, Lee Ling Lim2,3,10, Juliana C N Chan20,21,22,23.   

Abstract

BACKGROUND: Family history (FamH) of type 2 diabetes might indicate shared genotypes, environments, and/or behaviors. We hypothesize that FamH interacts with unhealthy behaviors to increase the risk of early onset of diabetes and poor cardiometabolic control.
METHODS: In a cross-sectional analysis of the prospective Joint Asia Diabetes Evaluation Register including patients from 427 clinics in 11 Asian countries/regions in 2007-2021, we defined positive FamH as affected parents/siblings and self-management as (1) healthy lifestyles (balanced diet, non-use of alcohol and tobacco, regular physical activity) and (2) regular self-monitoring of blood glucose (SMBG).
RESULTS: Among 86,931 patients with type 2 diabetes (mean±SD age: 56.6±11.6 years; age at diagnosis of diabetes: 49.8±10.5 years), the prevalence of FamH ranged from 39.1% to 85.3% in different areas with FamH affecting mother being most common (32.5%). The FamH group (n=51,705; 59.5%) was diagnosed 4.6 years earlier than the non-FamH group [mean (95% CI): 47.9 (47.8-48.0) vs. 52.5 (52.4-52.6), logrank p<0.001]. In the FamH group, patients with both parents affected had the earliest age at diagnosis [44.6 (44.5-44.8)], followed by affected single parent [47.7 (47.6-47.8)] and affected siblings only [51.5 (51.3-51.7), logrank p<0.001]. The FamH plus ≥2 healthy lifestyle group had similar age at diagnosis [48.2 (48.1-48.3)] as the non-FamH plus <2 healthy lifestyle group [50.1 (49.8-50.5)]. The FamH group with affected parents had higher odds of hyperglycemia, hypertension, and dyslipidemia than the FamH group with affected siblings, with the lowest odds in the non-FamH group. Self-management (healthy lifestyles plus SMBG) was associated with higher odds of attaining HbA1c<7%, blood pressure<130/80mmHg, and LDL-C<2.6 mmol/L especially in the FamH group (FamH×self-management, pinteraction=0.050-0.001).
CONCLUSIONS: In Asia, FamH was common and associated with young age of diagnosis which might be delayed by healthy lifestyle while self management  was associated with better control of  cardiometabolic risk factors especially in those with FamH.
© 2022. The Author(s).

Entities:  

Keywords:  Age of diagnosis; Cardiometabolic risks; Family history; Self-management; Type 2 diabetes

Mesh:

Year:  2022        PMID: 35831899      PMCID: PMC9281062          DOI: 10.1186/s12916-022-02424-y

Source DB:  PubMed          Journal:  BMC Med        ISSN: 1741-7015            Impact factor:   11.150


Background

In 2019, 9.3% of the global adult population were affected by diabetes with 50% living in Asia [1]. The majority had type 2 diabetes (95%) characterized by varying degrees of insulin resistance and deficiency [2], often accompanied by clustering of cardiometabolic risk factors [3]. Delayed diagnosis and management of diabetes can lead to poor quality of life, multimorbidity, and premature mortality [4, 5]. Young-onset type 2 diabetes diagnosed before age of 40 has become increasingly prevalent [6]. The growing burden of young-onset type 2 diabetes is multifactorial, including but not limited to genetics, perinatal factors, childhood obesity, and unhealthy lifestyles [6, 7]. In the clinic-based Joint Asia Diabetes Evaluation (JADE) Register, 1 in 5 Asian adults had young-onset type 2 diabetes [8], who had worse control of cardiometabolic risk factors than their peers with late-onset disease [6, 9]. In these young people, decades of exposure to cardiometabolic risk factors can lead to premature complications and death with socioeconomic implications [10]. Family history (FamH) is a strong risk factor for type 2 diabetes [11], evidenced by a higher concordance rate among monozygotic than dizygotic twins [12, 13]. People with FamH of diabetes had early onset of type 2 diabetes [14-18] and increased risks for hypertension, dyslipidemia, and obesity [19, 20]. Apart from shared genotypes, a FamH of diabetes might reflect shared behaviors and environment, such as lifestyles (physical inactivity, unhealthy diet, alcohol, and tobacco use) and socioeconomic status (education, employment, and household income) [20, 21]. On the other hand, some researchers had reported 40–80% reduced risk of type 2 diabetes associated with FamH, probably due to increased perceived risk and motivation to change lifestyles for mitigating risk [22]. Diabetes is a complex disease comprising of, but not limited to, genetic, perinatal, demographic, cognitive-psychosocial-behavioral, environmental, and ecological components with FamH being a proxy of some of these components [2], modified by self-management and access to care to influence age of diagnosis and clinical outcomes (Additional file 1: Figure S1) [2]. Despite this plausibility, there is a paucity of data on the interactive effects between FamH and behavioral factors on disease onset and cardiometabolic risks in type 2 diabetes. In this study, we hypothesize that FamH interacts with unhealthy lifestyles to bring forward age of diagnosis and together with suboptimal self-management, proxied by self-monitoring of blood glucose (SMBG), worsen control of cardiometabolic risk factors compared to those without FamH. We argue that while FamH per se is a non-modifiable risk factor, FamH can be used as a simple proxy to identify high-risk individuals for intensive lifestyle modification to delay disease onset and self-management support programs to improve control of cardiometabolic risk factors. We tested this hypothesis using data from a multicenter diabetes register in Asia with documentation of age of diagnosis, lifestyles, SMBG, and cardiometabolic risk factors.

Methods

Study design, setting, and participants

In this cross-sectional analysis, we curated data from the web-based, multi-country, prospective JADE Register, established as part of a quality improvement program to improve care and promote collaborative research in Asia [23]. The JADE Technology was established in 2007 by the Asia Diabetes Foundation, a non-profit research organization governed by the Chinese University of Hong Kong Foundation. The JADE portal adopted the same database structure of the Hong Kong Diabetes Register to guide structured data collection during a clinic visit for risk stratification and promotion of  personalized care. All participating sites were given an operating manual together with the case report form downloadable from the JADE portal which consists of details of rationale, purpose, and protocol including definitions and procedures of the JADE Program [23]. Patients with diabetes were recruited from 427 hospital- and community-based clinics in 11 Asian countries/regions (China, Hong Kong, India, Indonesia, Korea, Malaysia, Philippines, Singapore, Taiwan, Thailand, and Vietnam, refer to Table 1 in Additional file 1). The present study included patients who were (1) aged ≥18 years, (2) diagnosed with type 2 diabetes, and (3) enrolled between 2007 and 2021. All patients enrolled in the JADE Register had physician-diagnosed diabetes based on the American Diabetes Association criteria [24] and received routine care at the clinics. At the enrolment visit, patients attended the clinics after at least 8 h of fasting and underwent a structured interview by trained nurses using case report form with pre-defined fields and coded responses. This was followed by collection of fasting blood and early morning urine samples for laboratory assays as well as eye and feet examination according to the standardized JADE protocol. Patients with type 1 diabetes (defined as history of diabetic ketoacidosis and/or requirement of continuous insulin within one year of diagnosis) and unclassified diabetes were excluded [23, 25].

Exposures and covariates

Collected data included demographics (age and gender), age at diagnosis, types of diabetes, FamH of diabetes affecting first-degree relatives (father, mother, and siblings), education (primary school or below versus middle school or above), and employment (non-worker versus worker). FamH of diabetes in offsprings was not recorded. Use of medications (yes/no) including oral glucose-lowering drugs, insulin, lipid-lowering drugs, and blood pressure (BP)-lowering drugs was also recorded at enrolment. Self-reported lifestyle factors and regular SMBG were based on recall in the past 3 months using coded responses. We recorded the frequency of physical activity more than 30 min (none, <3 times, 3–4 times, 5 times, or >5 times weekly), adherence to a balanced  diet (yes, occasionally, or no), use of tobacco (never, ex-, or current smoker), and alcohol (never, ex-, occasional and regular drinker). Healthy lifestyles included adequate physical activity (30 min daily at least thrice weekly), adherence to a balanced  diet (yes), never or ex-smoker, and never or occasional drinker. Self-management was based on the aforementioned 4 lifestyle factors and SMBG (yes/no) and was defined by ≥3 of 5 favorable factors

Outcomes

The outcomes included age at diagnosis and cardiometabolic risk factors. Overnight fasting blood samples were collected for measuring fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), and lipid profile (total cholesterol, high-density lipoprotein cholesterol [HDL-C], calculated low-density lipoprotein cholesterol [LDL-C], and triglyceride). Cardiometabolic risks were defined as follows: hyperglycemia=HbA1c>7% (53 mmol/mol) or FPG>7 mmol/L; hypertension=BP≥140/90 mmHg and/or treatment with any BP-lowering drugs; dyslipidemia=LDL-C≥2.6 mmol/L, HDL-C<1.0 mmol/L in men or <1.3 mmol/L in women, triglycerides≥2.3 mmol/L and/or treatment with any lipid-lowering drugs. Optimal control was defined as attainment of ≥2 “ABC” targets (HbA1c<7%, BP<130/80 mmHg, LDL-C<2.6 mmol/L) [26, 27] which was associated with 30% reduction in incident cardiovascular disease in Chinese patients with type 2 diabetes [28].

Data analysis

Patients with complete FamH information (father, mother, and siblings) were included in the analysis. Descriptive statistics were presented as mean±SD or number (percentages) as appropriate. For between-group comparisons, we used the chi-square tests for categorical variables and the Independent t-tests for continuous variables. P-values adjusted for age, sex, and diabetes duration were further computed using regression methods. In this cross-sectional analysis of patients with diagnosed diabetes, age at  diagnosis (outcome) and effect of FamH (exposure) occurred before the data collection time-point. As reported by other workers [14], we used Kaplan-Meier estimation to compare the incidence of diabetes (y-axis) at each observed event time, i.e., age (x-axis) with log-rank p-value to provide a visual summary across all time-points. We stratified patients into four groups: (1) non-FamH group with <2 healthy lifestyles, (2) non-FamH group with ≥2 healthy lifestyles, (3) FamH group with <2 healthy lifestyles, and (4) FamH group with ≥2 healthy lifestyles and compared the mean age at diagnosis of type 2 diabetes with 95% confidence interval (95% CI). We performed sensitivity analysis by repeating the Kaplan-Meier analysis on patients diagnosed for less than 1 year prior to baseline assessment to minimize impact of care on behavioral changes. We conducted binary logistic regression to examine the associations of FamH with cardiometabolic profiles and attainment of “ABC” targets as dependent variables, adjusted for countries/regions, year of enrolment, demographics, socioeconomic status (education and employment), self-management, medication use, and duration of diabetes. We tested for interaction effects between FamH and self-management (lifestyle factors plus SMBG). Given that the interaction terms were not straightforward for interpretation by general readers, we conducted subgroup analysis to demonstrate whether the strength of associations of self-management with dependent variables varied between FamH and non-FamH groups, expressed as adjusted odds ratios (aOR) with 95%CI. We also performed stratified analyses to explore the consistency of the associations across countries/regions. All analyses were conducted using Statistical Package for Social Sciences (IBM, version 26) and R (version 4.0.2). A two-sided P value <0.05 was considered significant. Given the large sample size in the present study, listwise deletion was adopted for handling missing data.

Results

A total of 113,184 patients with diabetes were enrolled in the JADE Register from 2007 to 2021. After excluding patients with type 1 diabetes (n=1567) or unclassified diabetes (n=8310) and incomplete FamH data (n=16,376), we included 86,931 (76.8%) patients with type 2 diabetes [mean±SD age: 56.6±11.6 years, 53.5% men] in our final analysis (Table 1). Overall, 59.5% of the patients reported a positive FamH, with mother-only FamH being most common (13.2%), followed by siblings-only FamH (11.5%) and father-only FamH (9.8%). Among the 11 countries/regions, the prevalence of FamH ranged from 39.1 to 85.3% (Fig. 1). Compared with the non-FamH group, the FamH group was younger without sex preponderance (Table 1). They had better education (middle school or above) and were more likely to be actively employed and perform regular SMBG, but less likely to report a healthy lifestyle (healthy diet, never or ex-smoker, never or occasional alcohol drinker) (adjusted p-values<0.05).
Table 1

Profile of 86,931 patients with type 2 diabetes in the JADE Register between 2007 and 2021

MissingOverall (n = 86,931)Family history (n = 51,705)No family history (n = 35,226)Crude p-valueAdjusted p-value#
Country/region of recruitment
 India031,985 (36.8)19,911 (38.5)12,074 (34.3)<0.001<0.001
 Hong Kong023,076 (26.5)14,632 (28.3)8444 (24.0)
 Philippines11,167 (12.8)6578 (12.7)4589 (13.0)
 Vietnam6599 (7.6)2577 (5.0)4022 (11.4)
 China5563 (6.4)2572 (5.0)2991 (8.5)
 Taiwan2735 (3.1)1820 (3.5)915 (2.6)
 Indonesia01513 (1.7)940 (1.8)573 (1.6)
 Korea1497 (1.7)823 (1.6)674 (1.9)
 Malaysia01205 (1.4)1028 (2.0)177 (0.5)
 Thailand01048 (1.2)436 (0.8)612 (1.7)
 Singapore0543 (0.6)388 (0.8)155 (0.4)
Sociodemographic profile
 Age (years)6056.6 ± 11.655.2 ± 11.058.5 ± 12.0<0.001<0.001
 Age at  diagnosis of diabetes (years)628549.8 ± 10.547.9 ± 9.752.5 ± 10.9<0.001<0.001
 Diabetes duration (years)62828.18 ± 7.488.74 ± 7.667.35 ± 7.12<0.0010.011
 Sex—male646,487 (53.5)27,600 (53.4)18,887 (53.6)0.480<0.001
 Education
  Primary school or below250218,772 (22.2)9066 (18.0)9706 (28.4)<0.001<0.001
  Middle school and above65,657 (77.8)41,233 (82.0)24,424 (71.6)
 Employment status
  Non-worker76947,388 (55.0)26,663 (51.9)20,725 (59.6)<0.001<0.001
  Worker38,774 (45.0)24,745 (48.1)14,029 (40.4)
 Family history
  No family history035,226 (40.5)----
  Father only8534 (9.8)----
  Mother only11,432 (13.2)----
  Both parents3841 (4.4)----
  Siblings only9975 (11.5)----
  Father + siblings5200 (6.0)----
  Mother + siblings7379 (8.5)----
  Father + mothers + siblings5344 (6.1)----
Self-management (based on recall in last 3 months)
 Physical activity (30-min duration)2855
  <3 times per week46,445 (55.2)27,876 (55.4)18,569 (55.0)0.264<0.001
  ≥3 times per week37,631 (44.8)22,443 (44.6)15,188 (45.0)
 Adherence to a balanced diet3122
  Never or occasional40,577 (48.4)25,105 (50.0)15,472 (46.1)<0.001<0.001
  Always43,232 (51.6)25,111 (50.0)18,121 (53.9)
 Use of tobacco1027
  Never/Ex-smoker75,500 (87.9)44,633 (87.0)30,867 (89.2)<0.001<0.001
  Current smoker10,404 (12.1)6673 (13.0)3731 (10.8)
 Use of alcohol1159<0.001
  Never/occasional drinker65,749 (76.7)38,414 (75.0)27,335 (79.2)<0.001
  Ex-/regular drinker20,023 (23.3)12,835 (25.0)7188 (20.8)
 Self-monitoring of blood glucose823155,472 (70.5)34,715 (73.5)20,757 (65.9)<0.001<0.001
Biochemistry
 HbA1c (%)10,9018.00 ± 1.888.00 ± 1.828.00 ± 1.960.839<0.001
 HbA1c (mmol/mol)10,90164.0 ± 20.664.0 ± 19.964.0 ± 21.40.839<0.001
 Fasting plasma  glucose (mmol/L)96368.39 ± 3.188.45 ± 3.118.30 ± 3.28<0.0010.821
 Total cholesterol (mmol/L)15,3894.70 ± 1.164.68 ± 1.154.74 ± 1.19<0.001<0.001
 HDL-C (mmol/L)13,4261.21 ± 0.491.20 ± 0.411.24 ± 0.59<0.001<0.001
 LDL-C (mmol/L)13,6992.70 ± 1.152.68 ± 1.122.72 ± 1.20<0.0010.660
 Triglyceride (mmol/L)12,4721.91 ± 2.361.88 ± 2.411.95 ± 2.30<0.0010.151
 eGFR (ml/min/1.73m2)15,64382.0 ± 23.783.1 ± 23.680.5 ± 23.7<0.0010.307
 Urinary ACR (mg/mmol)30,79720.3 ± 82.020.0 ± 80.420.8 ± 84.10.2860.001
Cardiometabolic risk factors
 Systolic blood pressure (mmHg)1439131.0 ± 17.1131.0 ± 16.9131.0 ± 17.40.7580.875
 Diastolic blood pressure (mmHg)159978.9 ± 9.579.0 ± 9.578.7 ± 9.6<0.0010.003
 Body Mass Index (kg/m2)400526.2 ± 4.5526.4 ± 4.5026.0 ± 4.59<0.0010.197
 Hyperglycemiaa756763,397 (79.9)38,414 (81.1)24,983 (78.1)<0.0010.025
 Hypertensionb120555,618 (64.9)33,469 (65.5)22,149 (63.9)<0.001<0.001
 Dyslipidemiac941768,161 (87.9)40,991 (88.8)27,170 (86.7)<0.001<0.001
“ABC” treatment goalsd
 “A” goal achieved10,90125,810 (33.9)14,718 (32.9)11,092 (35.4)<0.0010.009
 “B” goal achieved157324,264 (28.4)14,633 (28.8)9631 (27.9)0.002<0.001
 “C” goal achieved13,69937,477 (51.2)22,323 (51.4)15,154 (50.8)0.1010.532
 ≥ 2 “ABC” goals achieved18,00523,062 (33.5)13,497 (33.4)9565 (33.5)0.672<0.001
Drug use at baseline
 Oral glucose-lowering drug072,318 (83.2)43,970 (85.0)28,348 (80.5)<0.001<0.001
 Insulin021,302 (24.5)13,322 (25.8)7980 (22.7)<0.001<0.001
 Lipid-regulating drug119741,985 (49.0)26,445 (51.6)15,540 (45.0)<0.001<0.001
 Blood pressure-lowering drug74047,003 (54.5)28,756 (55.9)18,247 (52.5)<0.001<0.001
 Renin-angiotensin system inhibitors029,199 (33.6)17,926 (34.7)11,273 (32.0)<0.001<0.001

Family history defined by diabetes affecting father, mother, and/or siblings

JADE Joint Asia Diabetes Evaluation, HbA1c glycated haemoglobin, eGFR estimated glomerular filtration rate, ACR albumin-creatinine ratio

Data were expressed as mean ± SD or number (%)

aHyperglycemia = HbA1c > 7% (53 mmol/mol) or fasting plasma glucose > 7 mmol/L

bHypertension = blood pressure ≥ 140/90 mmHg or on any blood pressure-lowering drugs

cDyslipidemia= LDL-C ≥ 2.6 mmol/L, HDL-C < 1 mmol/L, triglycerides ≥ 2.3 mmol/L, or on any lipid-regulating drugs

d“ABC” goals refer to HbA1c <7% (53 mmol/mol) (A), blood pressure <130/80 mmHg (B), and LDL-C <2.6 mmol/L (C)

#P-value adjusted for age, sex and diabetes duration

Fig. 1

Prevalence of family history among patients with type 2 diabetes across 11 Asian countries/regions. Figures at the end of the bars show the proportions of patients having family history of diabetes (father, mother, and/or siblings) in the corresponding countries/regions

Profile of 86,931 patients with type 2 diabetes in the JADE Register between 2007 and 2021 Family history defined by diabetes affecting father, mother, and/or siblings JADE Joint Asia Diabetes Evaluation, HbA1c glycated haemoglobin, eGFR estimated glomerular filtration rate, ACR albumin-creatinine ratio Data were expressed as mean ± SD or number (%) aHyperglycemia = HbA1c > 7% (53 mmol/mol) or fasting plasma glucose > 7 mmol/L bHypertension = blood pressure ≥ 140/90 mmHg or on any blood pressure-lowering drugs cDyslipidemia= LDL-C ≥ 2.6 mmol/L, HDL-C < 1 mmol/L, triglycerides ≥ 2.3 mmol/L, or on any lipid-regulating drugs d“ABC” goals refer to HbA1c <7% (53 mmol/mol) (A), blood pressure <130/80 mmHg (B), and LDL-C <2.6 mmol/L (C) #P-value adjusted for age, sex and diabetes duration Prevalence of family history among patients with type 2 diabetes across 11 Asian countries/regions. Figures at the end of the bars show the proportions of patients having family history of diabetes (father, mother, and/or siblings) in the corresponding countries/regions Figures 2 and 3 show the cumulative proportion defined by age at diagnosis across FamH groups. Overall, the FamH group was diagnosed 4.6 years earlier than the non-FamH group [mean (95% CI): 47.9 (47.8–48.0 years) vs. 52.5 (52.4–52.6) years] (Fig. 2). Patients with FamH affecting both parents with/without siblings had the earliest age at diagnosis [44.6 (44.5-44.8 years)], followed by FamH affecting single parent with/without siblings [47.7 (47.6-47.8 years)] and FamH affecting siblings only [51.5 (51.3-51.7 years)], with non-FamH group having the oldest age at diagnosis [52.5 (52.4-52.6 years)] (Fig. 3). The findings were consistent across the 11 countries/regions.
Fig. 2

Kaplan-Meier estimate of age at diagnosis stratified by presence of family history. FamH, family history of diabetes (father, mother, and/or siblings). The figure shows the mean age at diagnosis (years) in non-FamH group vs. FamH group in (A) overall study population [52.5, 95%CI 52.4–52.6] vs. [47.9, 95%CI 47.8–49.0], (B) China [53.7, 95%CI 53.3–54.1] vs. [49.6, 95%CI 49.2–50.0], (C) Hong Kong [54.6, 95%CI 54.3–54.8] vs. [49.0, 95%CI 48.8–49.2], (D) India [48.6, 95%CI 48.4–48.7] vs. [45.7, 95%CI 45.6–45.8], (E) Indonesia [53.6, 95%CI 52.7–54.6] vs. [49.8, 95%CI 49.2–50.5], (F) Korea [51.9, 95%CI 51.1–52.7] vs. [48.2, 95%CI 47.5–48.9], (G) Malaysia [53.4, 95%CI 51.9–55.0] vs. [47.9, 95%CI 47.3–48.6], (H) Philippines [55.3, 95%CI 54.9–55.6] vs. [49.7, 95%CI 49.4–50.0], (I) Singapore [53.1, 95%CI 51.3–54.8] vs. [46.9, 95%CI 45.7–48.0], (J) Taiwan [54.3, 95%CI 53.6–54.9] vs. [50.3, 95%CI 49.9–50.8], (K) Thailand [51.5, 95%CI 50.6–52.3] vs. [48.6, 95%CI 47.5–49.6], and (L) Vietnam [54.9, 95%CI 54.6–55.3] vs. [49.8, 95%CI 49.4–50.2]. All comparisons showed p<0.001 with log-rank test

Fig. 3

Kaplan-Meier estimate of age at diagnosis stratified by family history affecting parents and/or siblings. FamH, family history of diabetes (father, mother, and/or siblings). The figure shows the mean age at diagnosis (years) in non-FamH group vs. FamH group with affected siblings only vs. FamH group with affected single parent ± affected siblings vs. FamH group with affected both parents ± affected siblings in (A) overall study population [52.5, 95%CI 52.4–52.6] vs. [51.5, 95%CI 51.3–51.7] vs. [47.7, 95%CI 47.6–47.8] vs. [44.6, 95%CI 44.5–44.8], (B) China [53.7, 95%CI 53.3–54.1] vs. [53.3, 95%CI 52.6–54.0] vs. [48.4, 95%CI 47.9–48.8] vs. [46.1, 95%CI 45.0–47.2], (C) Hong Kong [54.6, 95%CI 54.3–54.8] vs. [52.8, 95%CI 52.4–53.2] vs. [48.7, 95%CI 48.5–48.9] vs. [45.7, 95%CI 45.3–46.1], (D) India [48.6, 95%CI 48.4–48.7] vs. [48.0, 95%CI 47.7–48.4] vs. [46.0, 95%CI 45.9–46.2] vs. [43.0, 95%CI 42.7–43.2], (E) Indonesia [53.6, 95%CI 52.7–54.6] vs. [53.2, 95%CI 51.7–54.6] vs. [49.5, 95%CI 48.6–50.3] vs. [47.4, 95%CI 45.7–49.1], (F) Korea [51.9, 95%CI 51.1–52.7] vs. [50.7, 95%CI 49.6–51.9] vs. [47.2, 95%CI 46.3–48.0] vs. [44.9, 95%CI 43.0–46.8], (G) Malaysia [53.4, 95%CI 51.9–55.0] vs. [51.2, 95%CI 49.6–52.7] vs. [48.2, 95%CI 47.4–49.1] vs. [45.4, 95%CI 44.2–46.7], (H) Philippines [55.3, 95%CI 54.9–55.6] vs. [53.5, 95%CI 52.9–54.1] vs. [49.0, 95%CI 48.7–49.3] vs. [46.7, 95%CI 46.0–47.4], (I) Singapore [53.1, 95%CI 51.3–54.8] vs. [50.9, 95%CI 47.9–54.0] vs. [46.4, 95%CI 45.0–47.8] vs. [45.8, 95%CI 43.4–48.1], (J) Taiwan [54.3, 95%CI 53.6–54.9] vs. [54.2, 95%CI 53.3–55.2] vs. [49.7, 95%CI 49.2–50.3] vs. [47.5, 95%CI 46.4–48.6], (K) Thailand [51.5, 95%CI 50.6–52.3] vs. [52.1, 95%CI 50.5–53.6] vs. [47.0, 95%CI 45.5–48.4] vs. [45.9, 95%CI 42.8–49.1], and (L) Vietnam [54.9, 95%CI 54.6–55.3] vs. [52.5, 95%CI 51.9–53.1] vs. [48.0, 95%CI 47.5–48.5] vs. [47.3, 95%CI 45.9–48.8]. All comparisons showed p <0.001 with log-rank test

Kaplan-Meier estimate of age at diagnosis stratified by presence of family history. FamH, family history of diabetes (father, mother, and/or siblings). The figure shows the mean age at diagnosis (years) in non-FamH group vs. FamH group in (A) overall study population [52.5, 95%CI 52.4–52.6] vs. [47.9, 95%CI 47.8–49.0], (B) China [53.7, 95%CI 53.3–54.1] vs. [49.6, 95%CI 49.2–50.0], (C) Hong Kong [54.6, 95%CI 54.3–54.8] vs. [49.0, 95%CI 48.8–49.2], (D) India [48.6, 95%CI 48.4–48.7] vs. [45.7, 95%CI 45.6–45.8], (E) Indonesia [53.6, 95%CI 52.7–54.6] vs. [49.8, 95%CI 49.2–50.5], (F) Korea [51.9, 95%CI 51.1–52.7] vs. [48.2, 95%CI 47.5–48.9], (G) Malaysia [53.4, 95%CI 51.9–55.0] vs. [47.9, 95%CI 47.3–48.6], (H) Philippines [55.3, 95%CI 54.9–55.6] vs. [49.7, 95%CI 49.4–50.0], (I) Singapore [53.1, 95%CI 51.3–54.8] vs. [46.9, 95%CI 45.7–48.0], (J) Taiwan [54.3, 95%CI 53.6–54.9] vs. [50.3, 95%CI 49.9–50.8], (K) Thailand [51.5, 95%CI 50.6–52.3] vs. [48.6, 95%CI 47.5–49.6], and (L) Vietnam [54.9, 95%CI 54.6–55.3] vs. [49.8, 95%CI 49.4–50.2]. All comparisons showed p<0.001 with log-rank test Kaplan-Meier estimate of age at diagnosis stratified by family history affecting parents and/or siblings. FamH, family history of diabetes (father, mother, and/or siblings). The figure shows the mean age at diagnosis (years) in non-FamH group vs. FamH group with affected siblings only vs. FamH group with affected single parent ± affected siblings vs. FamH group with affected both parents ± affected siblings in (A) overall study population [52.5, 95%CI 52.4–52.6] vs. [51.5, 95%CI 51.3–51.7] vs. [47.7, 95%CI 47.6–47.8] vs. [44.6, 95%CI 44.5–44.8], (B) China [53.7, 95%CI 53.3–54.1] vs. [53.3, 95%CI 52.6–54.0] vs. [48.4, 95%CI 47.9–48.8] vs. [46.1, 95%CI 45.0–47.2], (C) Hong Kong [54.6, 95%CI 54.3–54.8] vs. [52.8, 95%CI 52.4–53.2] vs. [48.7, 95%CI 48.5–48.9] vs. [45.7, 95%CI 45.3–46.1], (D) India [48.6, 95%CI 48.4–48.7] vs. [48.0, 95%CI 47.7–48.4] vs. [46.0, 95%CI 45.9–46.2] vs. [43.0, 95%CI 42.7–43.2], (E) Indonesia [53.6, 95%CI 52.7–54.6] vs. [53.2, 95%CI 51.7–54.6] vs. [49.5, 95%CI 48.6–50.3] vs. [47.4, 95%CI 45.7–49.1], (F) Korea [51.9, 95%CI 51.1–52.7] vs. [50.7, 95%CI 49.6–51.9] vs. [47.2, 95%CI 46.3–48.0] vs. [44.9, 95%CI 43.0–46.8], (G) Malaysia [53.4, 95%CI 51.9–55.0] vs. [51.2, 95%CI 49.6–52.7] vs. [48.2, 95%CI 47.4–49.1] vs. [45.4, 95%CI 44.2–46.7], (H) Philippines [55.3, 95%CI 54.9–55.6] vs. [53.5, 95%CI 52.9–54.1] vs. [49.0, 95%CI 48.7–49.3] vs. [46.7, 95%CI 46.0–47.4], (I) Singapore [53.1, 95%CI 51.3–54.8] vs. [50.9, 95%CI 47.9–54.0] vs. [46.4, 95%CI 45.0–47.8] vs. [45.8, 95%CI 43.4–48.1], (J) Taiwan [54.3, 95%CI 53.6–54.9] vs. [54.2, 95%CI 53.3–55.2] vs. [49.7, 95%CI 49.2–50.3] vs. [47.5, 95%CI 46.4–48.6], (K) Thailand [51.5, 95%CI 50.6–52.3] vs. [52.1, 95%CI 50.5–53.6] vs. [47.0, 95%CI 45.5–48.4] vs. [45.9, 95%CI 42.8–49.1], and (L) Vietnam [54.9, 95%CI 54.6–55.3] vs. [52.5, 95%CI 51.9–53.1] vs. [48.0, 95%CI 47.5–48.5] vs. [47.3, 95%CI 45.9–48.8]. All comparisons showed p <0.001 with log-rank test Figure 4 presents the combined associations of lifestyles and FamH with mean age at diagnosis. The non-FamH group with ≥2 healthy lifestyles had the oldest age at diagnosis [52.8 (52.7–52.9) years] while the FamH group with <2 healthy lifestyles had the earliest age at diagnosis [46.0 (45.8–46.2) years]. The FamH group with ≥2 healthy lifestyles had an age at diagnosis [48.2 (48.1–48.3) years] close to the non-FamH group with <2 healthy lifestyles [50.1 (49.8–50.5) years]. Similar patterns were observed in 11 Asian countries/regions. The results of sensitivity analysis (Additional file 1: Figure S2) including patients with type 2 diabetes diagnosed within 1 year before enrolment (n=8,556) were consistent with the overall analysis (n=86,931).
Fig. 4

Kaplan-Meier estimate of age at diagnosis stratified by combination of family history and healthy lifestyles. FamH, family history of diabetes (father, mother, and/or siblings). Healthy lifestyles include adequate physical activity (30 min at least 3 times weekly), adherence to a balanced diet, never or occasional alcohol drinker, and never or ex-smoker. The figure shows the mean age at diagnosis (years) in FamH- group with <2 healthy lifestyles vs. FamH− group with ≥2 healthy lifestyles vs. FamH+ group with <2 healthy lifestyles vs. FamH+ group with ≥2 healthy lifestyles in (A) overall study population [50.1, 95%CI 49.8–50.5] vs. [52.8, 95%CI 52.7–52.9] vs. [46.0, 95%CI 45.8–46.2] vs. [48.2, 95%CI 48.1–48.3], (B) China [53.0, 95%CI 51.5–54.5] vs. [57.4, 95%CI 56.3–58.4] vs. [50.2, 95%CI 48.6–51.8] vs. [54.3, 95%CI 53.1–55.4], (C) Hong Kong [56.0, 95%CI 54.4–57.6] vs. [59.5, 95%CI 58.7–60.2] vs. [52.0, 95%CI 51.1–53.0] vs. [54.5, 95%CI 54.0–55.0], (D) India [51.5, 95%CI 49.5–53.5] vs. [52.9, 95%CI 52.3–53.5] vs. [46.0, 95%CI 45.2–46.9] vs. [48.5, 95%CI 48.0–48.9], (E) Indonesia [52.8, 95%CI 47.9–57.6] vs. [58.8, 95%CI 56.6–60.9] vs. [50.2, 95%CI 45.6–54.8] vs. [58.0, 95%CI 55.5–60.4], (F) Korea [50.9, 95%CI 45.7–56.1] vs. [55.3, 95%CI 51.6–59.0] vs. [50.3, 95%CI 45.3–55.2] vs. [53.1, 95%CI 50.4–55.7], (G) Malaysia [52.4, 95%CI 47.1–57.7] vs. [53.2, 95%CI 51.6–54.8] vs. [45.7, 95%CI 43.8–47.6] vs. [48.2, 95%CI 47.5–48.9], (H) Philippines [53.7, 95%CI 51.8–55.6] vs. [58.6, 95%CI 57.7–59.5] vs. [51.6, 95%CI 49.9–53.2] vs. [53.7, 95%CI 52.9-54.5], (I) Singapore [53.0, 95%CI 53.0–53.0] vs. [59.4, 95%CI 54.4–64.4] vs. [53.3, 95%CI 49.2–57.3] vs. [55.2, 95%CI 52.5-57.9], (J) Taiwan [53, 95%CI 53–53] vs. [59.4, 95%CI 54.4–64.4] vs. [53.3, 95%CI 49.2–57.3] vs. [55.2, 95%CI 52.5-57.9], (K) Thailand [58.1, 95%CI 55.0–61.3] vs. [45.0, 95%CI 40.4–49.6] vs. [59.8, 95%CI 53.4–66.2] vs. [57.2, 95%CI 54.3–60.0], and (L) Vietnam [54.5, 95%CI 51.7–57.4] vs. [58.5, 95%CI 57.3–59.6] vs. [50.7, 95%CI 47.2–54.2] vs. [52.8, 95%CI 51.5–54.1]. All comparisons showed p <0.05 with log-rank test

Kaplan-Meier estimate of age at diagnosis stratified by combination of family history and healthy lifestyles. FamH, family history of diabetes (father, mother, and/or siblings). Healthy lifestyles include adequate physical activity (30 min at least 3 times weekly), adherence to a balanced diet, never or occasional alcohol drinker, and never or ex-smoker. The figure shows the mean age at diagnosis (years) in FamH- group with <2 healthy lifestyles vs. FamH− group with ≥2 healthy lifestyles vs. FamH+ group with <2 healthy lifestyles vs. FamH+ group with ≥2 healthy lifestyles in (A) overall study population [50.1, 95%CI 49.8–50.5] vs. [52.8, 95%CI 52.7–52.9] vs. [46.0, 95%CI 45.8–46.2] vs. [48.2, 95%CI 48.1–48.3], (B) China [53.0, 95%CI 51.5–54.5] vs. [57.4, 95%CI 56.3–58.4] vs. [50.2, 95%CI 48.6–51.8] vs. [54.3, 95%CI 53.1–55.4], (C) Hong Kong [56.0, 95%CI 54.4–57.6] vs. [59.5, 95%CI 58.7–60.2] vs. [52.0, 95%CI 51.1–53.0] vs. [54.5, 95%CI 54.0–55.0], (D) India [51.5, 95%CI 49.5–53.5] vs. [52.9, 95%CI 52.3–53.5] vs. [46.0, 95%CI 45.2–46.9] vs. [48.5, 95%CI 48.0–48.9], (E) Indonesia [52.8, 95%CI 47.9–57.6] vs. [58.8, 95%CI 56.6–60.9] vs. [50.2, 95%CI 45.6–54.8] vs. [58.0, 95%CI 55.5–60.4], (F) Korea [50.9, 95%CI 45.7–56.1] vs. [55.3, 95%CI 51.6–59.0] vs. [50.3, 95%CI 45.3–55.2] vs. [53.1, 95%CI 50.4–55.7], (G) Malaysia [52.4, 95%CI 47.1–57.7] vs. [53.2, 95%CI 51.6–54.8] vs. [45.7, 95%CI 43.8–47.6] vs. [48.2, 95%CI 47.5–48.9], (H) Philippines [53.7, 95%CI 51.8–55.6] vs. [58.6, 95%CI 57.7–59.5] vs. [51.6, 95%CI 49.9–53.2] vs. [53.7, 95%CI 52.9-54.5], (I) Singapore [53.0, 95%CI 53.0–53.0] vs. [59.4, 95%CI 54.4–64.4] vs. [53.3, 95%CI 49.2–57.3] vs. [55.2, 95%CI 52.5-57.9], (J) Taiwan [53, 95%CI 53–53] vs. [59.4, 95%CI 54.4–64.4] vs. [53.3, 95%CI 49.2–57.3] vs. [55.2, 95%CI 52.5-57.9], (K) Thailand [58.1, 95%CI 55.0–61.3] vs. [45.0, 95%CI 40.4–49.6] vs. [59.8, 95%CI 53.4–66.2] vs. [57.2, 95%CI 54.3–60.0], and (L) Vietnam [54.5, 95%CI 51.7–57.4] vs. [58.5, 95%CI 57.3–59.6] vs. [50.7, 95%CI 47.2–54.2] vs. [52.8, 95%CI 51.5–54.1]. All comparisons showed p <0.05 with log-rank test After adjusting for country, years of registration, demographics, education, employment status, lifestyles, SMBG, and medication use at registration, the FamH group had higher odds of hypertension (aOR 1.10, 95% CI 1.05–1.14) and dyslipidemia (aOR 1.19, 95% CI 1.13–1.26) but also higher odds of achieving the “A” goal (aOR 1.05, 95% CI 1.02–1.09), “B” goal (aOR 1.06, 95% CI 1.02–1.10), and ≥2 “ABC” goals (aOR 1.07, 95% CI 1.03–1.11), albeit with considerable inter-country variations (Fig. 5). Patients with affected parents with/without siblings also had higher adjusted odds of hyperglycemia, hypertension, and dyslipidemia compared to patients with affected siblings only (Fig. 6).
Fig. 5

Binary logistic regression of family history of diabetes on cardiometabolic profiles in different countries. All models were adjusted for age, sex, education (middle school and above vs. primary school or below), employment (worker vs. non-worker), drug use (oral glucose-lowering drug, insulin, lipid-regulating drug, blood pressure-lowering drug, and renin-angiotensin system inhibitors), physical activity, adherence to a balanced diet, alcohol use, smoking status, self-monitoring of blood glucose, duration of diabetes, and year of enrolment. The overall association was adjusted for the above variables and country/region of recruitment. Hyperglycemia = HbA1c > 7% (53 mmol/mol) or fasting plasma glucose > 7 mmol/L. Hypertension = blood pressure ≥ 140/90 mmHg or on any blood pressure-lowering drugs. Dyslipidemia= LDL-C ≥ 2.6 mmol/L, HDL-C < 1 mmol/L, triglycerides ≥ 2.3 mmol/L, or on any lipid-regulating drugs. “ABC” goals refer to HbA1c <7% (53 mmol/mol) (A), blood pressure <130/80 mmHg (B), and LDL-C <2.6 mmol/L (C). ***p<0.001, **p<0.01, *p<0.05; AOR = Adjusted odds ratios, 95% CI = 95% confidence interval

Fig. 6

Binary logistic regression of family history affecting parents and/or siblings on cardiometabolic profiles. All models were adjusted for age, sex, education (middle school and above vs. primary school or below), employment (worker vs. non-worker), drug use (oral glucose-lowering drug, insulin, lipid regulating drug, blood pressure-lowering drug, and renin-angiotensin system inhibitors), physical activity, adherence to a balanced diet, alcohol use, smoking status, self-monitoring of blood glucose, duration of diabetes, year of enrolment, and country/region of recruitment. Hyperglycemia = HbA1c > 7% (53 mmol/mol) or fasting plasma glucose > 7 mmol/L. Hypertension = blood pressure ≥ 140/90 mmHg or on any blood pressure-lowering drugs. Dyslipidemia= LDL-C ≥ 2.6 mmol/L, HDL-C < 1 mmol/L, triglycerides ≥ 2.3 mmol/L, or on any lipid-regulating drugs. “ABC” goals refer to HbA1c <7% (53 mmol/mol) (A), blood pressure <130/80 mmHg (B), and LDL-C <2.6 mmol/L (C). ***p<0.001, **p<0.01, *p<0.05. AOR = adjusted odds ratios, 95% CI = 95% confidence interval

Binary logistic regression of family history of diabetes on cardiometabolic profiles in different countries. All models were adjusted for age, sex, education (middle school and above vs. primary school or below), employment (worker vs. non-worker), drug use (oral glucose-lowering drug, insulin, lipid-regulating drug, blood pressure-lowering drug, and renin-angiotensin system inhibitors), physical activity, adherence to a balanced diet, alcohol use, smoking status, self-monitoring of blood glucose, duration of diabetes, and year of enrolment. The overall association was adjusted for the above variables and country/region of recruitment. Hyperglycemia = HbA1c > 7% (53 mmol/mol) or fasting plasma glucose > 7 mmol/L. Hypertension = blood pressure ≥ 140/90 mmHg or on any blood pressure-lowering drugs. Dyslipidemia= LDL-C ≥ 2.6 mmol/L, HDL-C < 1 mmol/L, triglycerides ≥ 2.3 mmol/L, or on any lipid-regulating drugs. “ABC” goals refer to HbA1c <7% (53 mmol/mol) (A), blood pressure <130/80 mmHg (B), and LDL-C <2.6 mmol/L (C). ***p<0.001, **p<0.01, *p<0.05; AOR = Adjusted odds ratios, 95% CI = 95% confidence interval Binary logistic regression of family history affecting parents and/or siblings on cardiometabolic profiles. All models were adjusted for age, sex, education (middle school and above vs. primary school or below), employment (worker vs. non-worker), drug use (oral glucose-lowering drug, insulin, lipid regulating drug, blood pressure-lowering drug, and renin-angiotensin system inhibitors), physical activity, adherence to a balanced diet, alcohol use, smoking status, self-monitoring of blood glucose, duration of diabetes, year of enrolment, and country/region of recruitment. Hyperglycemia = HbA1c > 7% (53 mmol/mol) or fasting plasma glucose > 7 mmol/L. Hypertension = blood pressure ≥ 140/90 mmHg or on any blood pressure-lowering drugs. Dyslipidemia= LDL-C ≥ 2.6 mmol/L, HDL-C < 1 mmol/L, triglycerides ≥ 2.3 mmol/L, or on any lipid-regulating drugs. “ABC” goals refer to HbA1c <7% (53 mmol/mol) (A), blood pressure <130/80 mmHg (B), and LDL-C <2.6 mmol/L (C). ***p<0.001, **p<0.01, *p<0.05. AOR = adjusted odds ratios, 95% CI = 95% confidence interval Self-management (healthy lifestyles plus SMBG) was associated with lower odds of hyperglycemia, hypertension, and dyslipidemia, and higher odds of attaining each “ABC” goal in both FamH and non-FamH groups, with greater strength of associations in the FamH group (Fig. 7F). The interaction term (FamH × self-management) was associated with lower odds of hypertension (aOR 0.90, 95% CI 0.82–0.98) and higher odds of achieving the “A” goal (aOR 1.10, 95% CI 1.00–1.20), “B” goal (aOR 1.20, 95% CI 1.10–1.31), “C” goal (aOR 1.18, 95% CI 1.08–1.28), and ≥ 2 “ABC” goals (aOR 1.19, 95% CI 1.08–1.30) (Additional file 1: Table S2). Subgroup analyses showed interaction between each behavior and FamH (Fig. 7A–D) except for SMBG with similar effect size in FamH and non-FamH group (Additional file 1: Table S2) while never or occasional use of alcohol was associated with lower odds of “A” and “B” goal achievement.
Fig. 7

Binary logistic regression of self-management stratified by family history on cardiometabolic profiles. Self-management was defined as ≥3 of 5 behavioral factors including adequate physical activity (30 min at least 3 times weekly), adherence to a balanced diet, never or occasional alcohol drinker, and never or ex-smoker, or self-monitoring of blood glucose. All models were adjusted for age, sex, education (middle school and above vs. primary school or below), employment (worker vs. non-worker), drug use (oral glucose-lowering drug, insulin, lipid regulating drug, blood pressure-lowering drug, and renin-angiotensin system inhibitors), duration of diabetes, year of enrolment, and country/region of recruitment. Hyperglycemia = HbA1c > 7% (53 mmol/mol) or fasting plasma glucose > 7 mmol/L. Hypertension = blood pressure ≥ 140/90 mmHg or on any blood pressure-lowering drugs. Dyslipidemia= LDL-C ≥ 2.6 mmol/L, HD-CL < 1 mmol/L, triglycerides ≥ 2.3 mmol/L, or on any lipid-regulating drugs. “ABC” goals refer to HbA1c <7% (53 mmol/mol) (A), blood pressure <130/80 mmHg (B), and LDL-C <2.6 mmol/L (C). ***p<0.001, **p<0.01, *p<0.05. FamH = family history of diabetes (father, mother, and/or siblings). AOR, adjusted odds ratios; 95% CI, 95% confidence interval

Binary logistic regression of self-management stratified by family history on cardiometabolic profiles. Self-management was defined as ≥3 of 5 behavioral factors including adequate physical activity (30 min at least 3 times weekly), adherence to a balanced diet, never or occasional alcohol drinker, and never or ex-smoker, or self-monitoring of blood glucose. All models were adjusted for age, sex, education (middle school and above vs. primary school or below), employment (worker vs. non-worker), drug use (oral glucose-lowering drug, insulin, lipid regulating drug, blood pressure-lowering drug, and renin-angiotensin system inhibitors), duration of diabetes, year of enrolment, and country/region of recruitment. Hyperglycemia = HbA1c > 7% (53 mmol/mol) or fasting plasma glucose > 7 mmol/L. Hypertension = blood pressure ≥ 140/90 mmHg or on any blood pressure-lowering drugs. Dyslipidemia= LDL-C ≥ 2.6 mmol/L, HD-CL < 1 mmol/L, triglycerides ≥ 2.3 mmol/L, or on any lipid-regulating drugs. “ABC” goals refer to HbA1c <7% (53 mmol/mol) (A), blood pressure <130/80 mmHg (B), and LDL-C <2.6 mmol/L (C). ***p<0.001, **p<0.01, *p<0.05. FamH = family history of diabetes (father, mother, and/or siblings). AOR, adjusted odds ratios; 95% CI, 95% confidence interval

Discussion

Based on hypothesis defined a priori, to the best of our knowledge, this is the first real-world evidence on the combined associations of  FamH and behavioral factors with  age at  diagnosis and control of cardiometabolic risk factors in Asian patients with type 2 diabetes. In this study, the proportion of patients with FamH of diabetes ranged from 39.1% in Vietnam to 85.3% in Malaysia, similar to the 40–60% prevalence of FamH reported from Korea, India, and Belgium [14-17], Overall, the FamH group was diagnosed 4.6 years younger than the non-FamH group which was the same as that reported in a Korean study [14]. In Sydney, other researchers also showed earlier age of diagnosis by 1.7 years for every 10% increase in affected family members [29]. The FamH plus unhealthy lifestyle group had the earliest age at diagnosis (46.0 years) while the non-FamH plus healthy lifestyle group had the oldest age at diagnosis (52.8 years). Interestingly, the FamH plus healthy lifestyle group (48.2 years) had similar age at diagnosis as the non-FamH plus unhealthy lifestyle group (50.1 years). This trend was found in both newly diagnosed patients and those with established diabetes. In part due to their younger age and active work-life, the FamH group was less likely to report healthy lifestyles with suboptimal control of cardiometabolic risk factors. While self-management (healthy lifestyle plus SMBG) was associated with better control of cardiometabolic risk factors and attainment of treatment goals in both FamH and non-FamH groups, this association was more marked in the FamH group with significant interaction. Although some researchers had specifically reported that healthy lifestyles might delay the onset of diabetes [30], no stratified analysis by FamH was reported. The proportions of patients with FamH vary amongst different countries/regions. This might reflect different levels of public awareness regarding the familial nature of diabetes and access to early detection programs. Despite differences in national income levels, health systems and access to medicines, care, and support, the interactions between FamH and self-management on age at diagnosis and control of cardiometabolic risk factors were consistent across all participating Asian countries or areas. In our study, 1 in 3 patients reported a maternal history of diabetes with or without other affected family members. This accords with the known risk associations of maternal hyperglycemia with early-onset diabetes in the offspring [2, 31], likely attributable to intrauterine effects of maternal obesity and gestational diabetes [6]. Apart from shared environment, lifestyles, common and rare genetic factors [32], chronic hepatitis B infection, and hemoglobinopathy (affecting 6–10% of the Asian population) with familial clustering were associated with increased risk of diabetes. These risk associations might be due to low grade inflammation and oxidative stress, which might contribute to the familial clustering of diabetes [33, 34]. In our literature search, we did not find direct evidence suggesting that FamH raised awareness resulting in early screening and younger age of diagnosis. Some researchers had reported that African Americans with FamH were more aware of risk factors for diabetes and more likely to consume fruits and vegetables and engage in diabetes screening [35]. This might lead to a younger age of diagnosis, especially in healthcare systems with easy access to screening service. However, in our study, patients with FamH were less likely to report healthy lifestyles, which might interact with genetic factors to bring forward age at  diagnosis. On the other hand, compared with those without FamH, they were more likely to perform SMBG. Given the benefits of peer support on self-management [36], we hypothesize that mutual support among affected family members might motivate increased use of SMBG to control blood glucose. In the International Diabetes Mellitus Practice Survey recruiting patients outside Europe and North America, SMBG was the only factor associated with attainment of HbA1c goal across all regions [27]. Data from the Taiwan Diabetes Registry also shows that SMBG was associated with higher odds of HbA1c<7% in patients with recently diagnosed type 2 diabetes [35]. Qualitative analysis through direct interview may provide more insights on differences in behavioral determinants such as values, perspectives, and concerns between people with or without FamH [2].

Implication

There is a wealth of randomized controlled trials showing that diabetes can be prevented in high-risk individuals, although few studies highlighted the delayed age at  diagnosis [2]. Although some researchers had specifically reported that healthy lifestyles might delay the onset of diabetes [30], no stratified analysis by FamH was reported. Results from our analysis suggested that FamH, especially affecting parents and/or siblings, brought forward the age at  diagnosis by nearly 5 years although this could be delayed by healthy lifestyles. Similarly, although patients with FamH had worse control of cardiometabolic risk factors than the non-FamH group, they appeared to benefit more from self-management (lifestyles plus SMBG). We leveraged the structured data collection of the JADE Register to explore the associations of FamH with age at diagnosis, cardiometabolic risks, and attainment of treatment targets, which if sustained, would reduce clinical events in the long term [28]. In this light, the JADE Register systematically gathered data in real-world practice to issue a personalized report complete with risk stratification (including FamH), complications, targets/trends of risk profile, and lifestyle factors to promote self-management and early intervention [36]. Self-management is the cornerstone in diabetes prevention and treatment [37]. In this analysis, patients with FamH and healthy lifestyles had an age at  diagnosis close to those without FamH and unhealthy lifestyles. Together with SMBG, these positive health behaviors had greater effect size in achieving treatment targets in patients with FamH than those without. While many experts advocate the use of biogenetic markers and algorithms to improve prediction, diagnosis, and management of patients with complex diseases such as type 2 diabetes [37], our data suggested that FamH is a simple proxy which can be used to identify high-risk individuals for intensive education and empowerment to delay disease onset and improve clinical outcomes.

Strength, limitations, and future study

The JADE Register enrolled patients from a wide range of hospital and community-based clinics in different countries with universal, subsidized, or private payment structures. This heterogeneity improved the generalizability of our findings across Asia. Our study has several limitations. First, the cross-sectional design precludes elucidation of a causal relationship of behavioral factors with age at diagnosis and cardiometabolic risks. Routine screening in some participating sites with specialized diabetes centers might have led to earlier diagnosis of patients with FamH. On the other hand, in some low- and middle-income countries where people have to pay out of pocket for screening, this might lead to delayed diagnosis. Although there was heterogeneity in health systems across the Asian regions, we had included region and year of enrolment as covariates in the regression models which yielded similar results on country-specific analysis. Given their exposure to an affected family member, the interaction between FamH and self-management on risk factor control is plausible. The negative associations between healthy lifestyle and age at  diagnosis might be confounded by behavioral changes after diagnosis although results were consistent in newly diagnosed patients. The JADE Register uses a pragmatic design to implement data-driven integrated care in a real-world setting [38, 39]. Thus, instead of using complex instruments, we used simple questionnaires based on available evidence to assess behavioral factors. The self-report of lifestyles and regular SMBG might be subject to social desirability bias although the use of coded responses in the case report form increased the internal validity. Recall bias might also introduce uncertainty of data such as age at diagnosis especially for silent disease such as diabetes. We also did not ascertain the FamH by confirming with the family members.

Conclusions

A FamH of diabetes is a complex indicator of the multicausality of type 2 diabetes. While FamH and non-white ethnicity are well-known risk factors for type 2 diabetes, for the first time, our real-world evidence had quantified the age at diagnosis in patients with or without FamH and their associations with cardiometabolic risks, with potential modification by self-management. Given the legacy effect of glycemic control on future clinical events [40, 41], early detection of prediabetes in family members of affected patients for lifestyle intervention might delay onset of diabetes. In patients with familial diabetes, promoting self-management might be particularly effective in controlling cardiometabolic risk factors. These results supported the recommendation of implementing a data-driven integrated diabetes program to adopt a family-based approach to detect, prevent, and treat diabetes focusing on empowerment with ongoing support [42]. Additional file 1: Table S1. [List of 427 hospital- and community-based clinics in 11 Asian countries/regions included]. Table S2. [Interaction effects of family history of diabetes and self-management on cardiometabolic risk factors]. Figure S1. [Conceptual framework of the complex interactions between family history and behavioral factors on development of type 2 diabetes and cardio-metabolic control]. Figure S2. [Kaplan–Meier estimate of cumulative proportion for age at diagnosis among 8,556 patients with type 2 diabetes diagnosed within 1 year prior to assessment].
  41 in total

Review 1.  Genomics, type 2 diabetes, and obesity.

Authors:  Mark I McCarthy
Journal:  N Engl J Med       Date:  2010-12-09       Impact factor: 91.245

2.  Is Diabetes Becoming the Biggest Epidemic of the Twenty-first Century?

Authors:  Syed Amin Tabish
Journal:  Int J Health Sci (Qassim)       Date:  2007-07

3.  Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.

Authors:  Pouya Saeedi; Inga Petersohn; Paraskevi Salpea; Belma Malanda; Suvi Karuranga; Nigel Unwin; Stephen Colagiuri; Leonor Guariguata; Ayesha A Motala; Katherine Ogurtsova; Jonathan E Shaw; Dominic Bright; Rhys Williams
Journal:  Diabetes Res Clin Pract       Date:  2019-09-10       Impact factor: 5.602

Review 4.  Family History of Type 2 Diabetes: Does Having a Diabetic Parent Increase the Risk?

Authors:  A K Papazafiropoulou; N Papanas; A Melidonis; E Maltezos
Journal:  Curr Diabetes Rev       Date:  2017

5.  Monitoring the targets of the St Vincent Declaration and the implementation of quality management in diabetes care: the DIABCARE initiative. The DIABCARE Monitoring Group of the St Vincent Declaration Steering Committee.

Authors:  K Piwernetz; P D Home; O Snorgaard; M Antsiferov; K Staehr-Johansen; M Krans
Journal:  Diabet Med       Date:  1993-05       Impact factor: 4.359

6.  Association between family history of diabetes and clusters of adherence to healthy behaviors: cross-sectional results from the Health Examinees-Gem (HEXA-G) study.

Authors:  Jaesung Choi; Ji-Yeob Choi; Sang-Ah Lee; Kyoung-Mu Lee; Aesun Shin; Juhwan Oh; JooYong Park; Minkyo Song; Jae Jeong Yang; Jong-Koo Lee; Daehee Kang
Journal:  BMJ Open       Date:  2019-06-16       Impact factor: 2.692

7.  Age at diagnosis, glycemic trajectories, and responses to oral glucose-lowering drugs in type 2 diabetes in Hong Kong: A population-based observational study.

Authors:  Calvin Ke; Thérèse A Stukel; Baiju R Shah; Eric Lau; Ronald C Ma; Wing-Yee So; Alice P Kong; Elaine Chow; Juliana C N Chan; Andrea Luk
Journal:  PLoS Med       Date:  2020-09-18       Impact factor: 11.069

8.  Effects of a Technology-Assisted Integrated Diabetes Care Program on Cardiometabolic Risk Factors Among Patients With Type 2 Diabetes in the Asia-Pacific Region: The JADE Program Randomized Clinical Trial.

Authors:  Lee-Ling Lim; Eric S H Lau; Amy W C Fu; Subir Ray; Yi-Jen Hung; Alexander T B Tan; Parinya Chamnan; Wayne H H Sheu; Manoj S Chawla; Yook-Chin Chia; Lee-Ming Chuang; Duc-Cong Nguyen; Aravind Sosale; Banshi D Saboo; Uday Phadke; Jothydev Kesavadev; Su-Yen Goh; Neeru Gera; Thi Thanh Huyen Vu; Ronald C W Ma; Vanessa Lau; Andrea O Y Luk; Alice P S Kong; Juliana C N Chan
Journal:  JAMA Netw Open       Date:  2021-04-01

9.  Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS).

Authors:  Juliana C N Chan; Juan Jose Gagliardino; Sei Hyun Baik; Jean-Marc Chantelot; Sandra R G Ferreira; Nicolae Hancu; Hasan Ilkova; Ambady Ramachandran; Pablo Aschner
Journal:  Diabetes Care       Date:  2008-11-25       Impact factor: 17.152

10.  The relationship between age of onset and risk factors including family history and life style in Korean population with type 2 diabetes mellitus.

Authors:  Jin-Won Noh; Jin Hee Jung; Jeong Eun Park; Jung Hwa Lee; Kang Hee Sim; Jumin Park; Min Hee Kim; Ki-Bong Yoo
Journal:  J Phys Ther Sci       Date:  2018-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.